



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2008. GMB 0501-0507
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Send to a collection of information unless it displays a valid GMB control number.

1733


TRANSMITTAL FORM

 TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/535,240	
	Filing Date	December 21, 2005	
	First Named Inventor	Neil Joseph ATKIN	
	Art Unit	1733	
	Examiner Name		
Total Number of Pages in This Submission	1	Attorney Docket Number	56108/315567

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Form PTO/SB/08 (01 sheet)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	2. 12 publications
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Kilpatrick Stockton LLP		
Signature			
Printed Name	Michael A. Bertelson		
Date	Aug. 18, 2006	Reg. No.	54,713


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	<u>Angela M. Rossi</u>		
Typed or printed name	Angela M. Rossi	Date	8/18/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Neil Joseph ATKIN et al.

SERIAL NO.: 10/535,240 Group Art Unit: 1733

FILED: December 21, 2005 Examiner:

FOR: ANGIOGENIC MEDICAL CYANOACRYLATE
ADHESIVE

Attorney Docket No.: 56108/315567

Date: 8/18/06

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the enclosed Form PTO/SB/08 are cited for consideration by the Examiner. Copies of the non-U.S. documents and miscellaneous documents are enclosed.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

U.S. Patent Application Serial No. 10/535,240

Filed: December 21, 2005

INFORMATION DISCLOSURE STATEMENT

Page 2


This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b), before the mailing date of an office action on the merits. Applicants believe that no fee is due for consideration of this paper. However, if a fee is due, the Commissioner is authorized to charge any fee due to Deposit Account No. 11-0855.

Respectfully submitted,



Michael A. Bertelson
Registration No. 54,713

KILPATRICK STOCKTON LLP
Suite 2800, 1100 Peachtree Street
Atlanta, Georgia 30309-4530
Phone (404) 815-6500



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/535,240
				Filing Date	December 21, 2005
				First Named Inventor	Neil Joseph ATKIN
				Art Unit	1733
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	41577/315567

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US 4,847,065	07-11-1989	Akimova, et al.	
		US 6,117,425	09-12-2000	MacPhee et al	
		US 6,152,141	11-28-2000	Stevens et al.	
		US 6,214,332	04-10-2001	Askill, et al.	
		US 6,224,622	05-01-2001	Kotzev	
		US 6,299,631	10-09-2001	Shalaby	
		US 6,316,523	11-13-2001	Hyon et al.	
		US 6,342,213	01-29-2002	Barley et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
		WO 86/06738	11-20-1986	Lazar	
		WO 97/16176	05-09-1997	Sefton, Michael	
		WO 00/67655	11-16-2000	Scimed Life Systems	
		WO 01/03607	01-18-2001	Scimed Life Systems, Inc.	
		EP 0 295 721	12-21-1988	The President and Fellows of Harvard College	
		WO 03/008003 A1	01-30-2003	Loma Linda Univ. Med. Ctr.	
		EP 0 530 804 A1 and B1	09-03-1992	Shaw, Robert Francis	
		GB 2 201 685 A	09-07-1988	2 Moskovsky Gosudaraivenny Meditsinsky Inst.	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		Bohmig, et al., 'Stable prodrugs of n-butyric acid: suppression of T cell alloresponses <i>in vitro</i> and prolongation of heart allograft survival in a fully allogenic rat strain combination,' <i>Transplant Immunology</i> , 7:221-227 (1999)				
		Chen, et al., 'Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Application in Differentiation Therapy, <i>Cancer Research</i> , 54:3494-3499 (1994)				
		Goldsmith, et al., 'Lipid Angiogenic Factor from Omentum, <i>JAMA</i> , 252:2034-2036 (1984)				
		Wilkinson, et al., 'Biosynthetic Regulation of Monobutyryl, an Adipocyte-secreted Lipid with Angiogenic Activity,' <i>J. Biol. Chem.</i> 266:16886-16891 (1991)				

Examiner Signature	Date Considered
--------------------	-----------------